8-KThe WireRoutine
Reg FD Disclosure
Filed Jun 22, 2026 · 12d ago · Accession 0001493152-26-029503
Plain English
LifeMD, Inc. announced a strategic co-marketing collaboration for a direct-to-patient self-pay program for XYOSTED® (testosterone enanthate) injection. The program will launch in July 2026 and will initially be available in 37 states.
Filing details
- Company
- LifeMD, Inc.
- Ticker
- LFMD
- CIK
- 948320
- Form type
- 8-K
- Filing date
- Jun 22, 2026
- Report date
- Jun 22, 2026
- Document
- form8-k.htm
- Size
- 364 KB